Accéder au contenu
Merck
Toutes les photos(1)

Documents

ABK0007

Sigma-Aldrich

HercBridge ELISA Kit

Synonyme(s) :

Protein Conformational Array Herceptin Biosimilar, Protein Conformational Array Trastuzumab

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
41116158
Nomenclature NACRES :
NA.32

Forme d'anticorps

IgG fraction of antiserum

Espèces réactives

human (Human IgG)

Conditions d'expédition

wet ice

Température de stockage

2-8°C

Description générale

A Protein Conformational Array (PCA) in a sandwich ELISA format where the plate is coated with a panel of antibodies raised against peptides derived from the full length protein sequence of Trastuzumab. Taken individually, each of these antibodies is strongly antigenic to the peptide sequence that was used in its production. However, when these peptides are incorporated into a full length correctly folded protein, the antigenicity of many of them is masked by the three dimensional structure of the protein and only a limited number of the antibodies respond. The result is a histogram which can be likened to a ‘fingerprint′ for correctly folded Trastuzumab. For a Herceptin Biosimilar, if the protein is correctly folded and glycosylated, the ‘fingerprint′ will match that of Trastuzumab. If it is not correctly folded, previously masked peptide sequences will be exposed and will be recognized by the antibody made to that exposed sequence. In this way, changes in the ‘fingerprint′ generated by the ELISA will point out differences between the Biosimilar and authentic Trastuzumab.

Application

For research use only. Not for use in diagnostic procedures.

Pictogrammes

Corrosion
GHS05

Mention d'avertissement

Warning

Mentions de danger

H290,H315,H319

Classification des risques

Eye Irrit. 2 - Met. Corr. 1 - Skin Irrit. 2

Code de la classe de stockage

8A - Combustible corrosive hazardous materials

Classe de danger pour l'eau (WGK)

WGK 1

Listes réglementaires

Les listes réglementaires sont principalement fournies pour les produits chimiques. Seules des informations limitées peuvent être fournies ici pour les produits non chimiques. L'absence d'indication signifie qu'aucun des composants n'est répertorié. Il incombe à l'utilisateur de s'assurer de l'utilisation sûre et légale du produit.

EU REACH Annex XVII (Restriction List)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Jihun Lee et al.
mAbs, 10(4), 547-571 (2018-02-28)
The evaluation of analytical similarity has been a challenging issue for the biosimilar industry because the number of lots for reference and biosimilar products available at the time of development are limited, whilst measurable quality attributes of target molecule are
Biosimilar mAb in-process Sample Higher Order Structure Analysis with Protein Conformational Array ELISA.
Michael Davies, Gan Wang, Jian Gong, Guofeng Fu and Xing Wang
Pharmaceut. Res., 1-11 (2016)
Yuanli Song et al.
mAbs, 10(3), 397-405 (2018-01-10)
The elucidation of antibody higher order structure (HOS) is critical in therapeutic antibody development. Since HOS determines the protein bioactivity and chemo-physical properties, this knowledge can help to ensure that the safety and efficacy attributes are not compromised. Protein conformational
Xing Wang et al.
Frontiers in pharmacology, 4, 103-103 (2013-08-24)
Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of
Soon Kwan Jung et al.
mAbs, 6(5), 1163-1177 (2014-12-18)
Remsima (infliximab) was recently approved as the world's first biosimilar monoclonal antibody (mAb) in both the European Union and Korea. To achieve this, extensive physicochemical characterization of Remsima in relation to Remicade was conducted in order to demonstrate the highly

Articles

Protein Conformation Array Multiplexing

Monoclonal antibodies (mAbs) lead biologics growth, predicted $125 billion worldwide sales by 2020, emphasizing their therapeutic significance.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique